Physician profile
Greg Towsley
NPI 1588653927
$1,416.17
in general payments reported to CMS, 2019-2025
22 companies · $234 in 2025
The $234 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $14.29 · 2021: $36.32 · 2022: $287 · 2023: $298 · 2024: $375 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815 · Education: $90.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $815.47 |
| Education | $90.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $277.12 | 2023-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $188.51 | 2019-2025 | Thinprep 2000 Processor, Aptima, Affirm Prone Biopsy System |
| Pfizer INC. | $174.45 | 2021-2024 | |
| Mayne Pharma Commercial LLC | $95.32 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $89.45 | 2019-2023 | |
| Exeltis, USA INC. | $85.29 | 2020-2024 | Slynd |
| Abbvie INC. | $50.99 | 2019-2022 | |
| Biogen, INC. | $48.78 | 2025 | Zurzuvae |
| Organon LLC | $48.17 | 2022-2025 | Nexplanon |
| Ascend Therapeutics US, LLC | $47.61 | 2019-2023 | |
| Avion Pharmaceuticals | $42.60 | 2022-2023 | Balcoltra |
| Therapeuticsmd, INC. | $41.17 | 2019 | |
| Millicent US INC | $37.22 | 2024 | Intrarosa, Femring |
| Coopersurgical, INC. | $30.15 | 2022 | |
| Covidien LP | $23.20 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $22.63 | 2023 | Gardasil 9 |
| Minerva Surgical, INC | $21.89 | 2022 | |
| Glaxosmithkline, LLC. | $21.51 | 2024 | Arexvy, Shingrix |
| Meditrina | $19.40 | 2025 | |
| Duchesnay USA Incorporated | $18.42 | 2019 | |
| Myovant Sciences INC. | $18.19 | 2022 | |
| Baxter Healthcare | $14.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greg Towsley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.